Literature DB >> 30137286

Rectal Insulin Instillation Inhibits Inflammation and Tumor Development in Chemically Induced Colitis.

Mohammad Yassin1, Zuzanna Sadowska1, Katerina Tritsaris1, Hannelouise Kissow2, Camilla H F Hansen3, Julie L Forman4, Gerhard Rogler5, Jesper T Troelsen6, Anders E Pedersen7, Jørgen Olsen1.   

Abstract

BACKGROUND AND AIMS: Epithelial expression of the insulin receptor in the colon has previously been reported to correlate with extent of colonic inflammation. However, the impact of insulin signalling in the intestinal mucosa is still unknown. Here, we investigated the effects of inactivating the epithelial insulin receptor in the intestinal tract, in an experimental model of inflammation-induced colorectal cancer.
METHODS: The mice were generated by utilizing the intestinal- and epithelial-specific villin promoter and the Cre-Lox technology. All mice included in the cohorts were generated by crossing [vil-Cre-INSR+/-] × [INSRfl/fl] to obtain [vil-Cre-INSR-/-], and their floxed littermates [INSRfl/fl] served as the control group. For the intervention study, phosphate-buffered saline with or without insulin was instilled rectally in anaesthetized wild-type mice with chemically induced colitis.
RESULTS: We found higher endoscopic colitis scores together with potentiated colonic tumorigenesis in the knockout mice. Furthermore, we showed that topically administered insulin in inflamed colons of wild-type mice reduced inflammation-induced weight loss and improved remission in a dose-dependent manner. Mice receiving rectal insulin enemas exhibited lower colitis endoscopic scores and reduced cyclooxygenase 2 mRNA expression, and developed significantly fewer and smaller tumours compared with the control group receiving phosphate-buffered saline only.
CONCLUSIONS: Rectal insulin therapy could potentially be a novel treatment, targeting the epithelial layer to enhance mucosal healing in ulcerated areas. Our findings open up new possibilities for combination treatments to synergize with the existing anti-inflammatory therapies.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30137286     DOI: 10.1093/ecco-jcc/jjy112

Source DB:  PubMed          Journal:  J Crohns Colitis        ISSN: 1873-9946            Impact factor:   9.071


  3 in total

1.  Dipeptidyl Peptidase 4 Inhibitors and Risk of Inflammatory Bowel Disease: Real-world Evidence in U.S. Adults.

Authors:  Tiansheng Wang; Jeff Y Yang; John B Buse; Virginia Pate; Huilin Tang; Edward L Barnes; Robert S Sandler; Til Stürmer
Journal:  Diabetes Care       Date:  2019-08-30       Impact factor: 19.112

2.  Intestinal insulin/IGF1 signalling through FoxO1 regulates epithelial integrity and susceptibility to colon cancer.

Authors:  A L Ostermann; C M Wunderlich; L Schneiders; M C Vogt; M A Woeste; B F Belgardt; C M Niessen; B Martiny; A C Schauss; P Frommolt; A Nikolaev; N Hövelmeyer; R C Sears; P J Koch; D Günzel; J C Brüning; F T Wunderlich
Journal:  Nat Metab       Date:  2019-03-04

3.  Host Gasdermin D restrains systemic endotoxemia by capturing Proteobacteria in the colon of high-fat diet-feeding mice.

Authors:  Yujie Shi; Yixin Zou; Yonghong Xiong; Shiyao Zhang; Mingming Song; Xiaofei An; Chang Liu; Wenxiang Zhang; Siyu Chen
Journal:  Gut Microbes       Date:  2021 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.